| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 46 | 2020 | 3523 | 3.000 |
Why?
|
| Myelodysplastic Syndromes | 25 | 2020 | 1352 | 2.830 |
Why?
|
| Spliceosomes | 4 | 2024 | 110 | 1.470 |
Why?
|
| Mutation | 41 | 2020 | 29786 | 1.120 |
Why?
|
| Alkylating Agents | 5 | 2014 | 139 | 1.100 |
Why?
|
| Hematopoietic Stem Cells | 15 | 2018 | 3386 | 0.890 |
Why?
|
| Ribonucleoproteins | 3 | 2015 | 381 | 0.840 |
Why?
|
| RNA Precursors | 3 | 2021 | 208 | 0.750 |
Why?
|
| Oncogene Proteins, Fusion | 8 | 2020 | 1581 | 0.710 |
Why?
|
| Genomics | 7 | 2018 | 5720 | 0.680 |
Why?
|
| Bone Marrow Cells | 9 | 2019 | 2513 | 0.590 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2016 | 222 | 0.580 |
Why?
|
| Clone Cells | 6 | 2018 | 1692 | 0.560 |
Why?
|
| Antigens, Ly | 5 | 2005 | 291 | 0.540 |
Why?
|
| Nuclear Proteins | 8 | 2018 | 5853 | 0.520 |
Why?
|
| RNA Splicing | 5 | 2021 | 907 | 0.520 |
Why?
|
| Caspase 9 | 1 | 2014 | 188 | 0.490 |
Why?
|
| Leukemia, Promyelocytic, Acute | 3 | 2011 | 236 | 0.460 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 4 | 2015 | 345 | 0.460 |
Why?
|
| Genes, Neoplasm | 4 | 2012 | 376 | 0.450 |
Why?
|
| Mice, Inbred Strains | 5 | 2010 | 1827 | 0.450 |
Why?
|
| Genetic Variation | 8 | 2016 | 6544 | 0.440 |
Why?
|
| Hematologic Neoplasms | 5 | 2021 | 1832 | 0.430 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2015 | 587 | 0.430 |
Why?
|
| Translocation, Genetic | 5 | 2014 | 1420 | 0.420 |
Why?
|
| Bone Marrow | 10 | 2020 | 2948 | 0.410 |
Why?
|
| Leukemia | 4 | 2024 | 1511 | 0.410 |
Why?
|
| Neoplasm Proteins | 5 | 2021 | 3703 | 0.390 |
Why?
|
| Leukemia, Myeloid | 4 | 2009 | 707 | 0.390 |
Why?
|
| Quantitative Trait Loci | 5 | 2012 | 2019 | 0.380 |
Why?
|
| Transcription Factor Brn-3A | 1 | 2010 | 12 | 0.380 |
Why?
|
| Germ-Line Mutation | 3 | 2015 | 1788 | 0.360 |
Why?
|
| Base Sequence | 12 | 2019 | 12797 | 0.360 |
Why?
|
| DNA Damage | 4 | 2018 | 2432 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2010 | 230 | 0.350 |
Why?
|
| Hematopoiesis | 6 | 2015 | 2072 | 0.340 |
Why?
|
| Alternative Splicing | 1 | 2014 | 1117 | 0.340 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2018 | 871 | 0.340 |
Why?
|
| Chromosome Deletion | 2 | 2015 | 1401 | 0.330 |
Why?
|
| Neoplasms, Experimental | 2 | 2021 | 1276 | 0.330 |
Why?
|
| Gene Dosage | 3 | 2009 | 1252 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2010 | 460 | 0.320 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2009 | 627 | 0.310 |
Why?
|
| Ribonuclease H | 2 | 2018 | 45 | 0.310 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2012 | 3920 | 0.310 |
Why?
|
| Gene Frequency | 7 | 2018 | 3588 | 0.310 |
Why?
|
| Genome, Human | 11 | 2015 | 4420 | 0.300 |
Why?
|
| Bone Marrow Transplantation | 6 | 2016 | 2765 | 0.300 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 1836 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2020 | 5442 | 0.300 |
Why?
|
| Mice | 34 | 2021 | 81183 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2009 | 403 | 0.300 |
Why?
|
| Cocarcinogenesis | 1 | 2006 | 54 | 0.290 |
Why?
|
| Mice, Transgenic | 9 | 2017 | 9734 | 0.280 |
Why?
|
| Neoplasms, Second Primary | 3 | 2009 | 1061 | 0.280 |
Why?
|
| Genes, p53 | 5 | 2018 | 755 | 0.280 |
Why?
|
| Genome | 5 | 2014 | 1808 | 0.280 |
Why?
|
| Azepines | 2 | 2019 | 336 | 0.280 |
Why?
|
| Antigens, CD34 | 4 | 2018 | 657 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2015 | 17446 | 0.260 |
Why?
|
| Chromosome Mapping | 5 | 2014 | 4740 | 0.260 |
Why?
|
| Single-Cell Analysis | 2 | 2019 | 2183 | 0.250 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 18029 | 0.240 |
Why?
|
| Animals | 41 | 2021 | 168757 | 0.240 |
Why?
|
| Sequence Analysis, DNA | 8 | 2014 | 4803 | 0.230 |
Why?
|
| Serine Endopeptidases | 4 | 1999 | 1072 | 0.230 |
Why?
|
| Ethylnitrosourea | 3 | 2014 | 51 | 0.230 |
Why?
|
| Gene Expression Profiling | 7 | 2016 | 9438 | 0.230 |
Why?
|
| Luminescent Proteins | 2 | 2004 | 853 | 0.230 |
Why?
|
| Radiotherapy | 2 | 2009 | 1533 | 0.230 |
Why?
|
| Pyrimidines | 3 | 2021 | 2942 | 0.220 |
Why?
|
| Receptors, Colony-Stimulating Factor | 2 | 2016 | 49 | 0.220 |
Why?
|
| Mutation, Missense | 2 | 2011 | 2564 | 0.220 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 18111 | 0.220 |
Why?
|
| Humans | 92 | 2024 | 744343 | 0.210 |
Why?
|
| Genes, Reporter | 2 | 2004 | 1547 | 0.210 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 2942 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 5535 | 0.200 |
Why?
|
| Graft vs Host Disease | 7 | 2016 | 2957 | 0.200 |
Why?
|
| Heterozygote | 3 | 2021 | 2804 | 0.200 |
Why?
|
| DNA | 3 | 2017 | 7301 | 0.190 |
Why?
|
| Transgenes | 2 | 2010 | 1009 | 0.190 |
Why?
|
| RNA, Neoplasm | 2 | 2021 | 769 | 0.190 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2021 | 131 | 0.190 |
Why?
|
| K562 Cells | 2 | 2021 | 634 | 0.180 |
Why?
|
| Blast Crisis | 1 | 2020 | 103 | 0.180 |
Why?
|
| Stem Cells | 3 | 2009 | 3567 | 0.180 |
Why?
|
| Karyotyping | 4 | 2019 | 1243 | 0.170 |
Why?
|
| Transplantation Conditioning | 5 | 2020 | 1598 | 0.160 |
Why?
|
| Locus Control Region | 1 | 1998 | 20 | 0.160 |
Why?
|
| Chromosome Aberrations | 2 | 2019 | 1813 | 0.160 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1998 | 1369 | 0.160 |
Why?
|
| Recurrence | 9 | 2019 | 8340 | 0.160 |
Why?
|
| Azacitidine | 2 | 2018 | 347 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 2948 | 0.160 |
Why?
|
| Myeloproliferative Disorders | 1 | 2004 | 606 | 0.160 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2010 | 496 | 0.160 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 214 | 0.160 |
Why?
|
| Middle Aged | 37 | 2019 | 213383 | 0.150 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 380 | 0.150 |
Why?
|
| Genes, MHC Class II | 1 | 2018 | 457 | 0.150 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2004 | 1116 | 0.150 |
Why?
|
| Globins | 1 | 1998 | 415 | 0.150 |
Why?
|
| Cyclohexylamines | 1 | 2017 | 21 | 0.150 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 1352 | 0.150 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2016 | 12 | 0.150 |
Why?
|
| Replication Protein A | 1 | 2017 | 52 | 0.150 |
Why?
|
| Alleles | 5 | 2021 | 6933 | 0.150 |
Why?
|
| Glutarates | 1 | 2018 | 236 | 0.150 |
Why?
|
| Species Specificity | 3 | 2010 | 2478 | 0.140 |
Why?
|
| Spiro Compounds | 1 | 2017 | 76 | 0.140 |
Why?
|
| DNA, Neoplasm | 4 | 2011 | 1758 | 0.140 |
Why?
|
| Germ Cells | 2 | 2014 | 631 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2018 | 640 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2019 | 11524 | 0.140 |
Why?
|
| Erythropoiesis | 1 | 2020 | 705 | 0.140 |
Why?
|
| Transplantation, Homologous | 8 | 2020 | 4776 | 0.140 |
Why?
|
| Cytarabine | 4 | 2019 | 692 | 0.140 |
Why?
|
| Membrane Proteins | 5 | 2005 | 7880 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2016 | 15519 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 1999 | 1821 | 0.130 |
Why?
|
| DNA Mutational Analysis | 10 | 2018 | 4186 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 9 | 2014 | 21827 | 0.130 |
Why?
|
| Lymphoma | 3 | 2018 | 1877 | 0.130 |
Why?
|
| Leukocytosis | 1 | 2016 | 247 | 0.130 |
Why?
|
| Male | 41 | 2020 | 350118 | 0.130 |
Why?
|
| Female | 45 | 2021 | 380194 | 0.130 |
Why?
|
| Aged | 28 | 2019 | 163280 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 689 | 0.130 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 720 | 0.130 |
Why?
|
| Cell Survival | 3 | 2018 | 5882 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2014 | 3617 | 0.130 |
Why?
|
| Adult | 33 | 2019 | 214055 | 0.130 |
Why?
|
| Epigenesis, Genetic | 4 | 2018 | 3647 | 0.130 |
Why?
|
| Pyrroles | 1 | 2021 | 1146 | 0.130 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2007 | 272 | 0.130 |
Why?
|
| HeLa Cells | 2 | 2018 | 3128 | 0.130 |
Why?
|
| Blood Cells | 2 | 2016 | 309 | 0.120 |
Why?
|
| Killer Cells, Natural | 2 | 2010 | 2133 | 0.120 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 6895 | 0.120 |
Why?
|
| Disease Progression | 8 | 2019 | 13284 | 0.120 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2010 | 651 | 0.120 |
Why?
|
| Transcription Factors | 3 | 2015 | 12208 | 0.120 |
Why?
|
| Gelatinases | 1 | 1993 | 94 | 0.120 |
Why?
|
| Idarubicin | 3 | 2019 | 62 | 0.120 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 2085 | 0.110 |
Why?
|
| Crosses, Genetic | 1 | 2014 | 791 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2018 | 914 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 16689 | 0.110 |
Why?
|
| Apoptosis | 4 | 2018 | 9727 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2017 | 695 | 0.110 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2014 | 286 | 0.110 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 491 | 0.110 |
Why?
|
| Skin | 5 | 2018 | 4364 | 0.110 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 1878 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2019 | 901 | 0.110 |
Why?
|
| Prognosis | 10 | 2020 | 29063 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2016 | 3597 | 0.100 |
Why?
|
| Sequence Deletion | 3 | 2011 | 1526 | 0.100 |
Why?
|
| Dioxygenases | 1 | 2014 | 316 | 0.100 |
Why?
|
| Janus Kinase 1 | 2 | 2011 | 104 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2010 | 2715 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1270 | 0.100 |
Why?
|
| RNA, Messenger | 5 | 2015 | 13033 | 0.100 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2011 | 43 | 0.100 |
Why?
|
| Codon | 2 | 2011 | 611 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 4 | 2005 | 2088 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 2020 | 2440 | 0.100 |
Why?
|
| Phenotype | 6 | 2016 | 16365 | 0.100 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily A | 1 | 2010 | 21 | 0.100 |
Why?
|
| Flow Cytometry | 3 | 2018 | 5974 | 0.090 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2010 | 82 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 12072 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 3798 | 0.090 |
Why?
|
| RNA | 2 | 2019 | 2749 | 0.090 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2011 | 232 | 0.090 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2010 | 40 | 0.090 |
Why?
|
| Affect | 2 | 2015 | 1476 | 0.090 |
Why?
|
| Aged, 80 and over | 11 | 2019 | 57776 | 0.090 |
Why?
|
| DNA, Complementary | 1 | 1993 | 2050 | 0.090 |
Why?
|
| Transfection | 2 | 2017 | 5892 | 0.090 |
Why?
|
| Transcription, Genetic | 2 | 2017 | 7722 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 1783 | 0.090 |
Why?
|
| Spleen | 2 | 2008 | 2362 | 0.090 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2012 | 544 | 0.090 |
Why?
|
| Transduction, Genetic | 2 | 2010 | 913 | 0.090 |
Why?
|
| Survival Analysis | 6 | 2018 | 10252 | 0.090 |
Why?
|
| Young Adult | 12 | 2020 | 56430 | 0.090 |
Why?
|
| Binding Sites | 2 | 2017 | 6114 | 0.090 |
Why?
|
| Cyclophosphamide | 3 | 2016 | 2242 | 0.090 |
Why?
|
| Cell Lineage | 2 | 2016 | 2504 | 0.080 |
Why?
|
| Plasmids | 1 | 2014 | 2307 | 0.080 |
Why?
|
| Genetic Engineering | 1 | 2015 | 951 | 0.080 |
Why?
|
| Granzymes | 4 | 1999 | 271 | 0.080 |
Why?
|
| Haploinsufficiency | 1 | 2011 | 328 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1993 | 1213 | 0.080 |
Why?
|
| Genes, X-Linked | 1 | 2009 | 128 | 0.080 |
Why?
|
| Neoplasms | 4 | 2022 | 21683 | 0.080 |
Why?
|
| DNA Methylation | 3 | 2011 | 4286 | 0.080 |
Why?
|
| Membrane Glycoproteins | 3 | 1999 | 3768 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2008 | 2455 | 0.080 |
Why?
|
| Remission Induction | 3 | 2020 | 2386 | 0.080 |
Why?
|
| Fetal Blood | 1 | 2014 | 1318 | 0.080 |
Why?
|
| Lymphocytes | 1 | 1996 | 2617 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3557 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 9239 | 0.080 |
Why?
|
| Gene Duplication | 1 | 2009 | 329 | 0.080 |
Why?
|
| Neutrophils | 3 | 2016 | 3719 | 0.080 |
Why?
|
| Oligonucleotide Probes | 1 | 2008 | 427 | 0.080 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 13695 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 1999 | 4479 | 0.080 |
Why?
|
| Algorithms | 1 | 2008 | 13881 | 0.070 |
Why?
|
| Haplotypes | 2 | 2010 | 2779 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 9648 | 0.070 |
Why?
|
| Multigene Family | 1 | 2010 | 1102 | 0.070 |
Why?
|
| Retroviridae | 1 | 2010 | 914 | 0.070 |
Why?
|
| Multifactorial Inheritance | 1 | 2014 | 1194 | 0.070 |
Why?
|
| Macular Degeneration | 1 | 2014 | 980 | 0.070 |
Why?
|
| CpG Islands | 1 | 2011 | 1172 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2005 | 648 | 0.070 |
Why?
|
| Chromosomes, Mammalian | 1 | 2006 | 151 | 0.070 |
Why?
|
| Mice, Knockout | 4 | 2021 | 14557 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2727 | 0.070 |
Why?
|
| Protein Binding | 2 | 2017 | 9386 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4751 | 0.070 |
Why?
|
| Mutagens | 1 | 2006 | 168 | 0.070 |
Why?
|
| DNA Probes | 1 | 2006 | 560 | 0.070 |
Why?
|
| X Chromosome | 1 | 2009 | 814 | 0.070 |
Why?
|
| Core Binding Factor alpha Subunits | 1 | 2005 | 25 | 0.060 |
Why?
|
| Exons | 1 | 2011 | 2437 | 0.060 |
Why?
|
| Adolescent | 9 | 2018 | 85781 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2021 | 4204 | 0.060 |
Why?
|
| Markov Chains | 1 | 2008 | 969 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2005 | 227 | 0.060 |
Why?
|
| Colony-Forming Units Assay | 1 | 2004 | 356 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2010 | 2716 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2015 | 3023 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2008 | 1588 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2010 | 2373 | 0.060 |
Why?
|
| Myoblasts | 1 | 2005 | 238 | 0.060 |
Why?
|
| Recombination, Genetic | 1 | 2009 | 1586 | 0.060 |
Why?
|
| Hydroxychloroquine | 1 | 2007 | 412 | 0.060 |
Why?
|
| Pore Forming Cytotoxic Proteins | 3 | 1999 | 130 | 0.060 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 1736 | 0.060 |
Why?
|
| Survival Rate | 4 | 2019 | 12788 | 0.060 |
Why?
|
| Leukemia, Experimental | 2 | 2016 | 246 | 0.060 |
Why?
|
| Perforin | 3 | 1999 | 168 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2004 | 1866 | 0.060 |
Why?
|
| Terminal Care | 1 | 2015 | 1694 | 0.060 |
Why?
|
| Organ Size | 1 | 2008 | 2252 | 0.060 |
Why?
|
| Caregivers | 1 | 2014 | 2094 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6538 | 0.050 |
Why?
|
| Graft Rejection | 1 | 1996 | 4397 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2007 | 4149 | 0.050 |
Why?
|
| Fetus | 1 | 2010 | 1880 | 0.050 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2004 | 263 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 675 | 0.050 |
Why?
|
| Computational Biology | 1 | 2014 | 3521 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2005 | 880 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 1708 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 903 | 0.050 |
Why?
|
| Neutropenia | 1 | 2007 | 895 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 2124 | 0.050 |
Why?
|
| Bone Marrow Diseases | 1 | 2003 | 231 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 2382 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 3022 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 13102 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 4554 | 0.050 |
Why?
|
| Endothelium | 1 | 2004 | 778 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2003 | 219 | 0.050 |
Why?
|
| Gene Targeting | 1 | 2004 | 880 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 2849 | 0.050 |
Why?
|
| Mammary Glands, Animal | 1 | 2002 | 276 | 0.050 |
Why?
|
| Child | 3 | 2018 | 77709 | 0.050 |
Why?
|
| Mice, 129 Strain | 2 | 2011 | 386 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2019 | 152 | 0.040 |
Why?
|
| Medical Oncology | 2 | 2022 | 2265 | 0.040 |
Why?
|
| beta-Galactosidase | 2 | 1998 | 573 | 0.040 |
Why?
|
| Ovarian Neoplasms | 2 | 2014 | 4838 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2006 | 1783 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2000 | 256 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 13815 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 518 | 0.040 |
Why?
|
| Complement Pathway, Alternative | 1 | 1999 | 126 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 2012 | 0.040 |
Why?
|
| Dogs | 1 | 2004 | 3912 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 2000 | 455 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 6171 | 0.040 |
Why?
|
| Bone Marrow Examination | 1 | 2018 | 157 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 641 | 0.040 |
Why?
|
| Workflow | 1 | 2022 | 847 | 0.040 |
Why?
|
| Erythroid Precursor Cells | 1 | 1998 | 218 | 0.040 |
Why?
|
| Acute Disease | 2 | 2005 | 7149 | 0.040 |
Why?
|
| Reticulocytes | 1 | 1998 | 290 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 892 | 0.040 |
Why?
|
| Incidence | 4 | 2009 | 20947 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2018 | 218 | 0.040 |
Why?
|
| Immunity, Cellular | 2 | 2010 | 1607 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 1998 | 344 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 1381 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2015 | 19229 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 1997 | 216 | 0.040 |
Why?
|
| Off-Label Use | 1 | 2018 | 169 | 0.040 |
Why?
|
| Quality of Life | 2 | 2015 | 12804 | 0.040 |
Why?
|
| Aging | 1 | 2015 | 8664 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2021 | 1899 | 0.040 |
Why?
|
| Splenomegaly | 1 | 2016 | 190 | 0.030 |
Why?
|
| Sweating | 1 | 2016 | 123 | 0.030 |
Why?
|
| 5-Methylcytosine | 1 | 2016 | 154 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 1998 | 4386 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2019 | 23403 | 0.030 |
Why?
|
| Cell Division | 4 | 2005 | 4568 | 0.030 |
Why?
|
| Daunorubicin | 1 | 2015 | 158 | 0.030 |
Why?
|
| Depression | 1 | 2015 | 7766 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2016 | 295 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 973 | 0.030 |
Why?
|
| Neoplastic Processes | 1 | 2014 | 35 | 0.030 |
Why?
|
| Mutagenesis | 2 | 2012 | 1266 | 0.030 |
Why?
|
| Exocytosis | 1 | 1996 | 353 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 474 | 0.030 |
Why?
|
| DNA Repair | 1 | 2024 | 2046 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 367 | 0.030 |
Why?
|
| Liver | 1 | 2010 | 7474 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2015 | 322 | 0.030 |
Why?
|
| Treatment Outcome | 6 | 2020 | 63114 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2014 | 3494 | 0.030 |
Why?
|
| Vincristine | 1 | 2016 | 1039 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 380 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2017 | 913 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1782 | 0.030 |
Why?
|
| Age of Onset | 2 | 2011 | 3271 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 39050 | 0.030 |
Why?
|
| Case-Control Studies | 4 | 2018 | 21746 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 19905 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 8428 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 5172 | 0.030 |
Why?
|
| Immunity | 1 | 2018 | 1012 | 0.030 |
Why?
|
| Genotype | 2 | 2019 | 12951 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2018 | 1301 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 4462 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 4933 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 684 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2429 | 0.020 |
Why?
|
| Chromosome Breakpoints | 1 | 2011 | 98 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 789 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 3129 | 0.020 |
Why?
|
| Hematocrit | 1 | 2012 | 636 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2018 | 3002 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 1993 | 4320 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2016 | 1915 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2017 | 10481 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4931 | 0.020 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2011 | 182 | 0.020 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 4328 | 0.020 |
Why?
|
| Platelet Count | 1 | 2012 | 781 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2011 | 373 | 0.020 |
Why?
|
| Gene Expression | 2 | 2010 | 7799 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2016 | 2234 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2010 | 768 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 437 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2459 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 1531 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 1620 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1997 | 1838 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2016 | 1951 | 0.020 |
Why?
|
| Breast Neoplasms | 3 | 2014 | 20822 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2010 | 399 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 498 | 0.020 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2009 | 165 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 11366 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2017 | 2967 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2010 | 323 | 0.020 |
Why?
|
| Introns | 1 | 2011 | 991 | 0.020 |
Why?
|
| Genome-Wide Association Study | 3 | 2012 | 12261 | 0.020 |
Why?
|
| Gene Fusion | 1 | 2011 | 371 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2018 | 53288 | 0.020 |
Why?
|
| RNA Interference | 1 | 2017 | 2889 | 0.020 |
Why?
|
| Oncogenes | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Age Factors | 2 | 2009 | 18370 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2011 | 450 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3586 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8642 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2007 | 320 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 2839 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2012 | 1534 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 1791 | 0.020 |
Why?
|
| HIV | 1 | 1993 | 1604 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1799 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2008 | 655 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2014 | 1940 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2488 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2018 | 77449 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2009 | 670 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2005 | 322 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2009 | 547 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5319 | 0.020 |
Why?
|
| Leukocytes | 1 | 2012 | 2043 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 6756 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2005 | 647 | 0.010 |
Why?
|
| Antigens, CD | 2 | 2010 | 4026 | 0.010 |
Why?
|
| Point Mutation | 1 | 2009 | 1623 | 0.010 |
Why?
|
| SEER Program | 1 | 2009 | 1508 | 0.010 |
Why?
|
| Risk Factors | 3 | 2019 | 72290 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3064 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2005 | 741 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2003 | 115 | 0.010 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2003 | 115 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2902 | 0.010 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 257 | 0.010 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2005 | 555 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 6386 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 12959 | 0.010 |
Why?
|
| Cell Count | 1 | 2005 | 1856 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2003 | 419 | 0.010 |
Why?
|
| Siblings | 1 | 2005 | 854 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2007 | 3701 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 10180 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 786 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 1785 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 5987 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13408 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 5181 | 0.010 |
Why?
|
| Cell Differentiation | 3 | 2005 | 11483 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2003 | 743 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2014 | 5102 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2015 | 3752 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 2915 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 242 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 23338 | 0.010 |
Why?
|
| Prednisone | 1 | 2003 | 1574 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 13989 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 2291 | 0.010 |
Why?
|
| Time Factors | 2 | 2017 | 40075 | 0.010 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1999 | 179 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 2505 | 0.010 |
Why?
|
| Methotrexate | 1 | 2003 | 1727 | 0.010 |
Why?
|
| United States | 2 | 2015 | 69872 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 12354 | 0.010 |
Why?
|
| Transcobalamins | 1 | 1995 | 18 | 0.010 |
Why?
|
| Hospitalization | 1 | 2014 | 10262 | 0.010 |
Why?
|
| Graft Survival | 1 | 2005 | 3737 | 0.010 |
Why?
|
| Lactoferrin | 1 | 1995 | 97 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 11031 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2009 | 40561 | 0.010 |
Why?
|
| Helper Viruses | 1 | 1993 | 58 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1993 | 156 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 12026 | 0.010 |
Why?
|
| Giant Cells | 1 | 1993 | 187 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1993 | 476 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1995 | 645 | 0.010 |
Why?
|
| Risk | 1 | 2005 | 9687 | 0.010 |
Why?
|
| Granulocytes | 1 | 1995 | 548 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 9146 | 0.010 |
Why?
|
| Peroxidase | 1 | 1995 | 611 | 0.010 |
Why?
|
| Mucins | 1 | 1995 | 564 | 0.010 |
Why?
|
| Cell Movement | 1 | 2003 | 5217 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 8324 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1993 | 862 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2002 | 3690 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 6622 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 14722 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1999 | 5524 | 0.000 |
Why?
|
| Kinetics | 1 | 1995 | 6473 | 0.000 |
Why?
|
| Virus Replication | 1 | 1993 | 2534 | 0.000 |
Why?
|
| Cell Line | 1 | 1993 | 15997 | 0.000 |
Why?
|
| Brain | 1 | 2003 | 26385 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 35421 | 0.000 |
Why?
|